Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?

Related Experiment Video

Updated: Mar 12, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Luca Paglialunga1, Zena Salih2, Biagio Ricciuti1

  • 1Department of Medical Oncology , Santa Maria della Misericordia Hospital , Perugia , Italy.

ESMO Open
|November 16, 2016
PubMed

Insights

Immune checkpoint inhibitors show promise for treating aggressive small cell lung cancer (SCLC). This review explores emerging evidence on CTLA-4 and PD-1 blockade for SCLC patients resistant to traditional therapies.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Small cell lung cancer (SCLC) is an aggressive malignancy with limited treatment advancements.
  • Platinum-based chemotherapy has plateaued in efficacy, necessitating novel therapeutic strategies.
  • Targeted therapies have not yielded significant clinical benefits for SCLC patients.

Approach:

  • This review synthesizes recent findings on immune checkpoint inhibitors in SCLC.
  • Evidence from early-phase clinical trials investigating CTLA-4 and PD-1 blockade is presented.

Key Points:

  • Immune checkpoint inhibitors, targeting CTLA-4 and PD-1, demonstrate promising preliminary results in SCLC.
  • These immunotherapies offer a potential new avenue for patients with treatment-resistant SCLC.
  • The review focuses on the emerging landscape of immunotherapy for SCLC.

Conclusions:

  • Immune checkpoint blockade represents a significant emerging strategy for small cell lung cancer.
  • Further research and clinical trials are warranted to establish the role of these inhibitors in SCLC management.
Keywords:
immune checkpointipilimumabnivolumabpembrolizumabsmall cell lung cancer

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K